trending Market Intelligence /marketintelligence/en/news-insights/trending/gZMo7cT1EY-k-J8XEsG1Lw2 content esgSubNav
In This List

US appeals court dismisses Amgen's demand to ban Sanofi, Regeneron drug

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


US appeals court dismisses Amgen's demand to ban Sanofi, Regeneron drug

The U.S. Court of Appeals for the Federal Circuit dismissed a permanent injunction on the sale of Sanofi and Regeneron Pharmaceuticals Inc.'s cholesterol-lowering drug Praluent, Reuters reported Oct. 5.

Amgen Inc., which markets a rival cholesterol drug, Repatha, had brought a lawsuit claiming that Praluent infringed on two of its patents related to a protein known as proprotein convertase subtilisin/kexin 9, or PCSK9.

U.S. District Judge Sue Robinson in Delaware granted Amgen's motion in January, banning Sanofi and Regeneron from selling and making Praluent in the U.S.

However, the U.S. Court of Appeals for the Federal Circuit in February allowed Praluent sales to continue while the firms sorted out the patent infringement suit.